Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Non Operating Income (2022 - 2026)

Sagimet Biosciences' Non Operating Income history spans 5 years, with the latest figure at $1.1 million for Q1 2026.

  • Quarterly Non Operating Income fell 37.06% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Mar 2026, down 38.07% year-over-year, with the annual reading at $5.9 million for FY2025, 34.16% down from the prior year.
  • Non Operating Income came in at $1.1 million for Q1 2026, down from $1.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.5 million in Q2 2024 to a low of $136000.0 in Q2 2022.
  • The 5-year median for Non Operating Income is $1.3 million (2023), against an average of $1.2 million.
  • Year-over-year, Non Operating Income skyrocketed 1101.69% in 2024 and then crashed 39.97% in 2025.
  • Sagimet Biosciences' Non Operating Income stood at $193000.0 in 2022, then surged by 581.35% to $1.3 million in 2023, then skyrocketed by 51.63% to $2.0 million in 2024, then plummeted by 39.97% to $1.2 million in 2025, then fell by 11.19% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Non Operating Income are $1.1 million (Q1 2026), $1.2 million (Q4 2025), and $1.4 million (Q3 2025).